{"nctId":"NCT02342171","briefTitle":"Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea","startDateStruct":{"date":"2015-02"},"conditions":["Hemorrhagic Fever, Ebola"],"count":606,"armGroups":[{"label":"Convalescent Plasma","type":"EXPERIMENTAL","interventionNames":["Other: Convalescent Plasma"]},{"label":"standard care","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Convalescent Plasma","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* PCR-confirmed, symptomatic infection with Ebola virus\n* Patient's, guardian's or representatives' willingness to provide written informed consent\n\nExclusion Criteria:\n\nA patient is not eligible to receive CP if they meet one of the following criteria:\n\n* History of allergic reaction to blood or plasma products (as judged by the investigator or treating physician);\n* Medical conditions in which receipt of additional fluid related to the transfusion (250-500 ml or in the case of children 10 ml/kg) may be detrimental to the patient (e.g. decompensated congestive heart failure or renal failure).\n* Patients in shock unresponsive to fluid challenge\n* Patients in shock with signs of multi-organ failure, defined as oliguria/anuria AND impaired consciousness AND/OR jaundice\n* Condition of patient where the procedure of plasma administration carries a risk for the staff","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Survival at Day 14 After Start of Intervention","description":"Effect of convalescent plasma in improving patients survival at day 14; it will be considered clinically significant if there is an absolute decrease in the case fatality rate of 20% or more, compared to SC alone","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"260","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With 30 Days Survival","description":"Effect of convalescent plasma in improving patients survival at day 30","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Titer of Ebola Viral RNA","description":"To assess the relationship between EVD antibody levels (EBOV IgG) in donated plasma and the changes in levels of viral RNA in patients who received Convalescent Plasma.\n\nThe outcome shows the overall association between antibody dose category and change in Cycle threshold (Ct) value pre and post transfusion (Ct is the number of cycles that have to be run before reaching a threshold value of a positive result).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Titer of Ebola Viral RNA","description":"To assess the relationship between EVD antibody levels (neutralizing antibodies) in donated plasma and the changes in levels of viral RNA in patients who received Convalescent Plasma.\n\nThe outcome shows the overall association between antibody dose category and change in Cycle threshold (Ct) value pre and post transfusion (Ct is the number of cycles that have to be run before reaching a threshold value of a positive result).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Died Corresponding to EV Antibody Levels (Anti-EBOV IgG)","description":"To assess the relationship between EVD antibody levels (anti-EBOV IgG) and death in patients who received Convalescent Plasma","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Died Corresponding to EV Antibody Levels (Neutralizing Antibodies)","description":"To assess the relationship between EVD antibody levels (neutralizing antibodies) and death in patients who received CP","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Transfusion-related Serious Adverse Reactions (SARs)","description":"To assess the occurrence of serious adverse reactions (SARs) related to CP transfusion in Ebola patients","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Professional Safety Incidents","description":"To assess the occurrence of safety risks related to CP transfusion in health workers administering the treatments. This will be observed throughout the study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality Risk Factor: Ct","description":"To determine Ct as risk factor for mortality despite administration of CP.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality Risk Factor: Age","description":"To determine age as risk factor for mortality despite administration of CP.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":84},"commonTop":["Increase in temperature","Itching or skin rash","Nausea"]}}}